Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2090-911X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer ; volume:75 ; number:1 ; day:13 ; month:2 ; year:2023 ; pages:1-9 ; date:12.2023
The Egyptian heart journal ; 75, Heft 1 (13.2.2023), 1-9, 12.2023

Creator: Levicki, Rea
Lovrić Benčić, Martina
Ivanac Vranešić, Irena
Bradić, Lada
Begovac, Marta
Jug, Juraj
Dedić Plavetić, Natalija

Contributor: SpringerLink (Online service)

DOI: 10.1186/s43044-023-00331-y

URN: urn:nbn:de:101:1-2023041609560025674903

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Levicki, Rea
Lovrić Benčić, Martina
Ivanac Vranešić, Irena
Bradić, Lada
Begovac, Marta
Jug, Juraj
Dedić Plavetić, Natalija
SpringerLink (Online service)

Other Objects (12)

Corrected QT interval and QT dispersion in temporal lobe epilepsy

Plasma homocysteine levels associated with a corrected QT interval

Arzneimittel Profil Trastuzumab-Deruxtecan

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Prevalence and risk factors of prolonged corrected QT interval in general Chinese population

Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose

Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Shorter course of trastuzumab: Caveat emptor

Trastuzumab administration during pregnancy: an update

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)

Corrected QT interval and QT dispersion in temporal lobe epilepsy

Plasma homocysteine levels associated with a corrected QT interval

Arzneimittel Profil Trastuzumab-Deruxtecan

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Prevalence and risk factors of prolonged corrected QT interval in general Chinese population

Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose

Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Shorter course of trastuzumab: Caveat emptor

Trastuzumab administration during pregnancy: an update

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)

Corrected QT interval and QT dispersion in temporal lobe epilepsy

Plasma homocysteine levels associated with a corrected QT interval

Arzneimittel Profil Trastuzumab-Deruxtecan

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Prevalence and risk factors of prolonged corrected QT interval in general Chinese population

Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose

Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Shorter course of trastuzumab: Caveat emptor

Trastuzumab administration during pregnancy: an update

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Corrected QT interval and QT dispersion in temporal lobe epilepsy

Plasma homocysteine levels associated with a corrected QT interval

Arzneimittel Profil Trastuzumab-Deruxtecan

Arzneimittel Profil Trastuzumab-Deruxtecan

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Prevalence and risk factors of prolonged corrected QT interval in general Chinese population

Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose

Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Shorter course of trastuzumab: Caveat emptor

Trastuzumab administration during pregnancy: an update

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)

Corrected QT interval and QT dispersion in temporal lobe epilepsy

Plasma homocysteine levels associated with a corrected QT interval

Arzneimittel Profil Trastuzumab-Deruxtecan

Arzneimittel Profil Trastuzumab-Deruxtecan

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Prevalence and risk factors of prolonged corrected QT interval in general Chinese population

Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose

Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Shorter course of trastuzumab: Caveat emptor

Trastuzumab administration during pregnancy: an update

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)

Corrected QT interval and QT dispersion in temporal lobe epilepsy

Plasma homocysteine levels associated with a corrected QT interval

Arzneimittel Profil Trastuzumab-Deruxtecan

Arzneimittel Profil Trastuzumab-Deruxtecan

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Prevalence and risk factors of prolonged corrected QT interval in general Chinese population

Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose

Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Shorter course of trastuzumab: Caveat emptor

Trastuzumab administration during pregnancy: an update

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)

Related objects

Reset password